
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific demonstrates a robust growth trajectory, evidenced by impressive sales increases across multiple product lines, including a 35% year-over-year growth in Watchman sales and a 63% increase in electrophysiology (EP) sales due to market share gains. The company's guidance for Q4 indicates organic sales growth of 11-13% year-over-year, alongside anticipated GAAP EPS between $0.48 and $0.52, reflecting strong financial health and operational efficiency. Additionally, promising indicators such as expected sales exceeding $60 million for Nalu in 2025, with a targeted growth rate surpassing 25% in 2026, underscore a positive long-term outlook for Boston Scientific's market position and revenue potential.
Bears say
Boston Scientific faces a challenging financial outlook driven by several key factors, including anticipated foreign exchange headwinds projected at approximately $0.04 per share, which complicates revenue growth expectations. The company's reliance on its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) portfolios, which operate in mature markets experiencing persistent pricing pressure, raises concerns regarding sustainable growth and profitability. Additionally, setbacks in product launches and integration of acquisitions may hinder the firm's ability to meet both internal targets and consensus expectations, further undermining future growth prospects.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares